The termination removes a low-probability revenue opportunity tied to a future generic launch, but has no near-term financial impact. Monitor VIVITROL exclusivity status and any third-party ANDA activity for future generic competition risk.
Drug in focus
ALKS drug pipeline →VIVITROL
● Neutral Named in this 8-K- Impact
- Phase
- Approved
- Time to market
- Already marketed (FDA-approved 2006 for alcohol dependence; 2010 for opioid dependence)
- Next catalyst
- None dated
What to watchWatch for the January 2027 Teva generic entry, this will pressure Vivitrol's ~$457M annual revenue stream. Monitor the antitrust lawsuit (Value Drug, filed Oct 2025) which could accelerate generic competition. The stock has run ~97% from its 52-week low and trades near its high; consider whether the diversification story (LUMRYZ, alixorexton orexin agonist in Phase 3) adequately offsets the Vivitrol cliff.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 8 $54.29entry
- T+1 · 4mo ago −0.94%α −1.79% · $53.78
- T+5 · 4mo ago −4.95%α −5.82% · $51.60
- T+20 · 3mo ago −8.92%α −12.19% · $49.45
- T+60 · 7w ago −25.33%α −27.82% · $40.54
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Alkermes and Amneal Pharmaceuticals mutually terminated the Authorized Generic Product Supply Agreement for VIVITROL (naltrexone ER injectable suspension) after Amneal failed to meet certain terms and declined to order any batches. No penalties were incurred, and all claims were released. The agreement, which was contingent on a third-party ANDA product launch, had no revenue generated and no financial impact.
Key Facts
- Agreement terminated July 6, 2026, with Amneal not ordering any batches
- No penalties incurred by Alkermes; all claims released between parties
- Agreement was for a limited authorized generic version of VIVITROL, contingent on third-party ANDA launch
- No financial impact reported, no revenue was ever generated under the agreement
Financial Impact
Zero, no payments, penalties, or obligations remain. The agreement was never operationalized (no batches ordered).
Risk Factors
- Termination does not eliminate the risk of future generic competition to VIVITROL from other ANDA filers
- No material financial consequence, market reaction likely muted
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (ALKS), Batch item 1 | 0001193125-26-298004 |
| Document: 0001193125-26-298004-index-headers.html | 0001193125-26-298004 |
| Document: 0001193125-26-298004-index.html | 0001193125-26-298004 |
| Document: 0001193125-26-298004.txt | 0001193125-26-298004 |
| 8-K Filing (ALKS), Batch item 5 | 0001193125-26-298004 |
| Document: 0001193125-26-298004-index-headers.html | 0001193125-26-298004 |
| Document: 0001193125-26-298004-index.html | 0001193125-26-298004 |
| Document: 0001193125-26-298004.txt | 0001193125-26-298004 |
Track record
23 reports on ALKS
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +25.88% at T+60 after the May 12, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Neutral 4/10 Entry $46.98 Now $46.53 −0.96% settles Feb 10
- Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $44.54 Now $46.53 +4.47% settles Feb 3
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $45.89 Now $46.53 +1.39% settles Feb 2
- Nov 3, 202613d ago 8-K Neutral 5/10 Entry $45.69 Now $46.53 +1.84% settles Feb 1
- Sep 21, 20268w ago 8-K Bullish 6/10 Entry $44.00 Now $46.53 +5.76% settles Dec 15
- Sep 16, 20268w ago 8-K Neutral 2/10 Entry $46.07 Now $46.53 +1.00% settles Dec 10
- Sep 3, 202610w ago Insider Cluster Neutral 2/10 Entry $46.10 Now $46.53 +0.93% settles Dec 1
- Aug 3, 202615w ago Insider Cluster Bearish 4/10 Entry $49.67 to $44.32 Now $46.53 +6.32% ▲ +10.77% +11.15% vs SPY
- Aug 3, 202615w ago Insider Cluster Neutral 2/10 Entry $49.67 to $44.32 Now $46.53 −6.32% ▼ −10.77% −11.15% vs SPY
- Aug 3, 202615w ago Insider Cluster Neutral 3/10 Entry $49.67 to $44.32 Now $46.53 −6.32% ▼ −10.77% −11.15% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers